These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 8797600)

  • 21. The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the TAG72 antigen.
    Xiang J; Liu E; Delbaere LT; Chen Z; Luo X; Qi Y; Rathgeber C
    Cancer Biother; 1993; 8(3):253-62. PubMed ID: 7804366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a human IgA antibody specific for the tumour antigen TAG-72.
    Ingram PE; Owens RJ; Woof JM
    Biochem Soc Trans; 1997 May; 25(2):330S. PubMed ID: 9191375
    [No Abstract]   [Full Text] [Related]  

  • 23. Conversion of an anti-single-stranded DNA active site to an anti-fluorescein active site through heavy chain complementarity determining region transplantation.
    Gulliver GA; Bedzyk WD; Smith RG; Bode SL; Tetin SY; Voss EW
    J Biol Chem; 1994 Mar; 269(11):7934-40. PubMed ID: 8132513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and activity of phosphorylatable human interferon-alpha B2 and interferon-alpha A/D.
    Wang P; Izotova L; Mariano TM; Donnelly RJ; Pestka S
    J Interferon Res; 1994 Feb; 14(1):41-6. PubMed ID: 8027592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of a bifunctional hybrid molecule B72.3/metallothionein-1 by protein engineering.
    Xiang J; Koropatnick J; Qi Y; Luo X; Moyana T; Li K; Chen Y
    Immunology; 1993 Apr; 78(4):574-81. PubMed ID: 8495976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimerization of Mu-9: a colon-specific antigen-p antibody reactive with gastrointestinal carcinomas.
    Krishnan IS; Hansen HJ; Losman MJ; Goldenberg DM; Leung SO
    Cancer; 1997 Dec; 80(12 Suppl):2667-74. PubMed ID: 9406723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3.
    Couto JR; Blank EW; Peterson JA; Kiwan R; Padlan EA; Ceriani RL
    Adv Exp Med Biol; 1994; 353():55-9. PubMed ID: 7985542
    [No Abstract]   [Full Text] [Related]  

  • 28. Modification in framework region I results in a decreased affinity of chimeric anti-TAG72 antibody.
    Xiang JH; Roder J; Pan ZG; Roifman C; Hozumi N
    Mol Immunol; 1991; 28(1-2):141-8. PubMed ID: 2011123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Creation of phosphorylation sites in proteins: construction of a phosphorylatable human interferon alpha.
    Li BL; Langer JA; Schwartz B; Pestka S
    Proc Natl Acad Sci U S A; 1989 Jan; 86(2):558-62. PubMed ID: 2911594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction and phosphorylation of a fusion protein Hu-IFN-alpha A/gamma.
    Zhao XX; Li BL; Langer JA; Van Riper G; Pestka S
    Anal Biochem; 1989 May; 178(2):342-7. PubMed ID: 2502045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rapid procedure for the humanization of monoclonal antibodies.
    Sandhu JS
    Gene; 1994 Dec; 150(2):409-10. PubMed ID: 7821819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein.
    Boleti E; Deonarain MP; Spooner RA; Smith AJ; Epenetos AA; George AJ
    Ann Oncol; 1995 Nov; 6(9):945-7. PubMed ID: 8624300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue.
    Banerjee RK; van Osdol WW; Bungay PM; Sung C; Dedrick RL
    J Control Release; 2001 Jul; 74(1-3):193-202. PubMed ID: 11489495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of phosphorylatable chimeric monoclonal antibody CC49 with a casein kinase I recognition site.
    Lin L; Gillies SD; Schlom J; Pestka S
    Protein Expr Purif; 1999 Feb; 15(1):83-91. PubMed ID: 10024474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of phosphorylatable monoclonal antibody CC49 with a casein kinase II recognition site.
    Lin L; Gillies SD; Schlom J; Pestka S
    Anticancer Res; 1998; 18(6A):3971-8. PubMed ID: 9891433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of phosphorylatable chimeric monoclonal antibody CC49.
    Lin L; Gillies SD; Lan Y; Izotova L; Wu W; Schlom J; Pestka S
    Int J Oncol; 1998 Jul; 13(1):115-20. PubMed ID: 9625812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The construction of a mouse/human chimeric antibody against human breast cancer cells.
    Meulemans E; Vandevyver C; Volckaert G; Raus J
    Year Immunol; 1993; 7():131-6. PubMed ID: 8372502
    [No Abstract]   [Full Text] [Related]  

  • 38. Construction of phosphorylatable chimeric monoclonal antibody CC49 with a tyrosine srC kinase recognition site.
    Lin L; Gillies SD; Schlom J; Pestka S
    Int J Oncol; 1998 Oct; 13(4):725-32. PubMed ID: 9735402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of phosphorylatable monoclonal antibody to a tumor-associated antigen.
    Lin L; Daugherty B; Schlom J; Pestka S
    Cancer Res; 1996 Sep; 56(18):4250-4. PubMed ID: 8797600
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.